Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper "BET bromodomain inhibition as a therapeutic strategy to target c-Myc" (Delmore et al., 2011). Here we report the results of those experiments. We found that treatment of human multiple myeloma (MM) cells with the small-molecular inhibitor of BET bromodomains, (+)-JQ1, selectively downregulated MYC transcription, which is similar to what was reported in the original study (Figure 3B; Delmore et al., 2011). Efficacy of (+)-JQ1 was evaluated in an orthotopically xenografted model of MM. Overall survival was increased in (+)-JQ1 treated mice compared to vehicle control, similar to the original study (Figure 7E; Delmore et al., 2011). Tumor burden, as determined by bioluminescence, was decreased in (+)-JQ1 treated mice compared to vehicle control; however, while the effect was in the same direction as the original study (Figure 7C-D; Delmore et al., 2011), it was not statistically significant. The opportunity to detect a statistically significant difference was limited though, due to the higher rate of early death in the control group, and increased overall survival in (+)-JQ1 treated mice before the pre-specified tumor burden analysis endpoint. Additionally, we evaluated the (−)-JQ1 enantiomer that is structurally incapable of inhibiting BET bromodomains, which resulted in a minimal impact on MYC transcription, but did not result in a statistically significant difference in tumor burden or survival distributions compared to treatment with (+)-JQ1. Finally, we report meta-analyses for each result.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laboratory of Toxicology, F. O. P., Chuong, P.-H., Nguyen, L. A., Department of Pharmacy, L. S. P. C. H., He, H., & Department of Analytical Chemistry, C. P. U. (2006) · International Journal of Biomedical Science · doi:10.59566/ijbs.2006.2085 · Cited by 1,224
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · cited 2×
“, 2016), and triple negative breast cancer (da Motta et al., 2016; Shu et al., 2016).”
BackgroundBET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545 · cited 2×
“Acquired resistance to BET inhibitors have also been reported (Fong et al., 2015; Kumar et al., 2015; Rathert et al., 2015), with recent studies suggesting combinatorial drug treatment to overcome resistance mechanisms (Asangani et al., 2016; Kurimchak et al., 2016; Yao et al., 2015).”
BackgroundThe Costs of using Unauthenticated, Over-Passaged Cell Lines: How Much more Data do we Need?
Hughes, P., Marshall, D., Reid, Y., Parkes, H., & Gelber, C. (2007) · BioTechniques · doi:10.2144/000112598 · Cited by 434 · cited 2×
“These include variables such as cell line genetic drift (Hughes et al., 2007; Kleensang et al., 2016), as well as subclonal drift in heterogeneous stable cells (Shearer and Saunders, 2015), circadian biological responses to therapy (Fu and Kettner, 2013), the microbiome of recipient mice (Macpherson and McCoy, 2015),…”
BackgroundThe circadian clock in cancer development and therapy
Fu, L., & Kettner, N. M. (2013) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-396971-2.00009-9 · Cited by 251
Vaux, D. L., Fidler, F., & Cumming, G. (2012) · The EMBO Reports · doi:10.1038/embor.2012.36 · Cited by 155
Kleensang, A., Vantangoli, M. M., Odwin-DaCosta, S., Andersen, M. E., Boekelheide, K., Bouhifd, M., Fornace, A. J., Li, H.-H., Livi, C. B., Madnick, S., et al. (2016) · Scientific Reports · doi:10.1038/srep28994 · Cited by 114
Cited by
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Challenges for assessing replicability in preclinical cancer biology
Errington, T. M., Denis, A., Perfito, N., Iorns, E., & Nosek, B. A. (2021) · eLife · doi:10.7554/elife.67995 · Cited by 267
Bustin, S., & Nolan, T. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12801 · Cited by 113
Can cancer researchers accurately judge whether preclinical reports will reproduce?
Benjamin, D., Mandel, D. R., & Kimmelman, J. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2002212 · Cited by 32
Metadata
- Authors
- Aird, F., Kandela, I., Mantis, C., & Reproducibility Project: Cancer Biology
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2017-01-19
- Volume
- 6
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W2578098988
- Cited by
- 45
- References
- 7
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. https://app.cochat.ai/papers/10.7554/elife.21253
- The paper
- Aird, F., Kandela, I., Mantis, C., & Reproducibility Project: Cancer Biology. (2017). Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. eLife. https://doi.org/10.7554/elife.21253
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.